Skip to main content
PMC home page
Journal of Virology logoLink to Journal of Virology
. 1995 Jul;69(7):4006–4011. doi: 10.1128/jvi.69.7.4006-4011.1995

The enhancer in the long control region of human papillomavirus type 16 is up-regulated by PEF-1 and down-regulated by Oct-1.

G J Sibbet 1, S Cuthill 1, M S Campo 1
PMCID: PMC189133  PMID: 7769658

Abstract

The minimal enhancer in the long control region of human papillomavirus type 16 regulates cell type and constitutive expression from the promoter P97. This region contains at least four DNase I footprints (fp4e, fp5e, fp6e, and fp7e). We have shown that fp5e is crucial to enhancer function and have described an apparently novel factor (PEF-1) binding fp5e (S. Cuthill, G. J. Sibbet, and M. S. Campo, Mol. Carcinog. 8:9-104, 1993). Further analyses reveal that Oct-1 or an Oct-related factor binds fp5e at a site overlapping that of PEF-1. The binding of Oct-1 to fp5e has been demonstrated by electrophoretic mobility shift assays, by oligonucleotide competition studies, and by using an Oct-1-specific anti-POU serum. The location of the Oct-1 site has been confirmed by a panel of mutants across fp5e. Mutations that block PEF-1 binding to fp5e also block enhancer/promoter activity of the long control region, whereas mutations that block Oct-1 binding significantly increase enhancer/promoter activity. Thus, although both PEF-1 and Oct-1 interact with fp5e, they appear to regulate human papillomavirus expression in opposite ways.

Full Text

The Full Text of this article is available as a PDF (332.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersen B., Schonemann M. D., Flynn S. E., Pearse R. V., 2nd, Singh H., Rosenfeld M. G. Skn-1a and Skn-1i: two functionally distinct Oct-2-related factors expressed in epidermis. Science. 1993 Apr 2;260(5104):78–82. doi: 10.1126/science.7682011. [DOI] [PubMed] [Google Scholar]
  2. Apt D., Chong T., Liu Y., Bernard H. U. Nuclear factor I and epithelial cell-specific transcription of human papillomavirus type 16. J Virol. 1993 Aug;67(8):4455–4463. doi: 10.1128/jvi.67.8.4455-4463.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bosch F. X., Schwarz E., Boukamp P., Fusenig N. E., Bartsch D., zur Hausen H. Suppression in vivo of human papillomavirus type 18 E6-E7 gene expression in nontumorigenic HeLa X fibroblast hybrid cells. J Virol. 1990 Oct;64(10):4743–4754. doi: 10.1128/jvi.64.10.4743-4754.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1006/abio.1976.9999. [DOI] [PubMed] [Google Scholar]
  5. Böhm S., Wilczynski S. P., Pfister H., Iftner T. The predominant mRNA class in HPV16-infected genital neoplasias does not encode the E6 or the E7 protein. Int J Cancer. 1993 Nov 11;55(5):791–798. doi: 10.1002/ijc.2910550517. [DOI] [PubMed] [Google Scholar]
  6. Chan W. K., Chong T., Bernard H. U., Klock G. Transcription of the transforming genes of the oncogenic human papillomavirus-16 is stimulated by tumor promotors through AP1 binding sites. Nucleic Acids Res. 1990 Feb 25;18(4):763–769. doi: 10.1093/nar/18.4.763. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Chong T., Apt D., Gloss B., Isa M., Bernard H. U. The enhancer of human papillomavirus type 16: binding sites for the ubiquitous transcription factors oct-1, NFA, TEF-2, NF1, and AP-1 participate in epithelial cell-specific transcription. J Virol. 1991 Nov;65(11):5933–5943. doi: 10.1128/jvi.65.11.5933-5943.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Chong T., Chan W. K., Bernard H. U. Transcriptional activation of human papillomavirus 16 by nuclear factor I, AP1, steroid receptors and a possibly novel transcription factor, PVF: a model for the composition of genital papillomavirus enhancers. Nucleic Acids Res. 1990 Feb 11;18(3):465–470. doi: 10.1093/nar/18.3.465. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cripe T. P., Alderborn A., Anderson R. D., Parkkinen S., Bergman P., Haugen T. H., Pettersson U., Turek L. P. Transcriptional activation of the human papillomavirus-16 P97 promoter by an 88-nucleotide enhancer containing distinct cell-dependent and AP-1-responsive modules. New Biol. 1990 May;2(5):450–463. [PubMed] [Google Scholar]
  10. Cuthill S., Sibbet G. J., Campo M. S. Characterization of a nuclear factor, papilloma enhancer binding factor-1, that binds the long control region of human papillomavirus type 16 and contributes to enhancer activity. Mol Carcinog. 1993;8(2):96–104. doi: 10.1002/mc.2940080206. [DOI] [PubMed] [Google Scholar]
  11. Ephrussi A., Church G. M., Tonegawa S., Gilbert W. B lineage--specific interactions of an immunoglobulin enhancer with cellular factors in vivo. Science. 1985 Jan 11;227(4683):134–140. doi: 10.1126/science.3917574. [DOI] [PubMed] [Google Scholar]
  12. Faus I., Hsu H. J., Fuchs E. Oct-6: a regulator of keratinocyte gene expression in stratified squamous epithelia. Mol Cell Biol. 1994 May;14(5):3263–3275. doi: 10.1128/mcb.14.5.3263. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Gloss B., Chong T., Bernard H. U. Numerous nuclear proteins bind the long control region of human papillomavirus type 16: a subset of 6 of 23 DNase I-protected segments coincides with the location of the cell-type-specific enhancer. J Virol. 1989 Mar;63(3):1142–1152. doi: 10.1128/jvi.63.3.1142-1152.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Gloss B., Yeo-Gloss M., Meisterenst M., Rogge L., Winnacker E. L., Bernard H. U. Clusters of nuclear factor I binding sites identify enhancers of several papillomaviruses but alone are not sufficient for enhancer function. Nucleic Acids Res. 1989 May 11;17(9):3519–3533. doi: 10.1093/nar/17.9.3519. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Goldsborough A. S., Healy L. E., Copeland N. G., Gilbert D. J., Jenkins N. A., Willison K. R., Ashworth A. Cloning, chromosomal localization and expression pattern of the POU domain gene Oct-11. Nucleic Acids Res. 1993 Jan 11;21(1):127–134. doi: 10.1093/nar/21.1.127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Haugen T. H., Cripe T. P., Ginder G. D., Karin M., Turek L. P. Trans-activation of an upstream early gene promoter of bovine papilloma virus-1 by a product of the viral E2 gene. EMBO J. 1987 Jan;6(1):145–152. doi: 10.1002/j.1460-2075.1987.tb04732.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Hoppe-Seyler F., Butz K. Cellular control of human papillomavirus oncogene transcription. Mol Carcinog. 1994 Jul;10(3):134–141. doi: 10.1002/mc.2940100304. [DOI] [PubMed] [Google Scholar]
  18. Hoppe-Seyler F., Butz K., zur Hausen H. Repression of the human papillomavirus type 18 enhancer by the cellular transcription factor Oct-1. J Virol. 1991 Oct;65(10):5613–5618. doi: 10.1128/jvi.65.10.5613-5618.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Iftner T., Oft M., Böhm S., Wilczynski S. P., Pfister H. Transcription of the E6 and E7 genes of human papillomavirus type 6 in anogenital condylomata is restricted to undifferentiated cell layers of the epithelium. J Virol. 1992 Aug;66(8):4639–4646. doi: 10.1128/jvi.66.8.4639-4646.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Ishiji T., Lace M. J., Parkkinen S., Anderson R. D., Haugen T. H., Cripe T. P., Xiao J. H., Davidson I., Chambon P., Turek L. P. Transcriptional enhancer factor (TEF)-1 and its cell-specific co-activator activate human papillomavirus-16 E6 and E7 oncogene transcription in keratinocytes and cervical carcinoma cells. EMBO J. 1992 Jun;11(6):2271–2281. doi: 10.1002/j.1460-2075.1992.tb05286.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. List H. J., Patzel V., Zeidler U., Schopen A., Rühl G., Stollwerk J., Klock G. Methylation sensitivity of the enhancer from the human papillomavirus type 16. J Biol Chem. 1994 Apr 22;269(16):11902–11911. [PubMed] [Google Scholar]
  22. Mack D. H., Laimins L. A. A keratinocyte-specific transcription factor, KRF-1, interacts with AP-1 to activate expression of human papillomavirus type 18 in squamous epithelial cells. Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9102–9106. doi: 10.1073/pnas.88.20.9102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Morris P. J., Dent C. L., Ring C. J., Latchman D. S. The octamer binding site in the HPV16 regulatory region produces opposite effects on gene expression in cervical and non-cervical cells. Nucleic Acids Res. 1993 Feb 25;21(4):1019–1023. doi: 10.1093/nar/21.4.1019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. O'Connor M., Bernard H. U. Oct-1 activates the epithelial-specific enhancer of human papillomavirus type 16 via a synergistic interaction with NFI at a conserved composite regulatory element. Virology. 1995 Feb 20;207(1):77–88. doi: 10.1006/viro.1995.1053. [DOI] [PubMed] [Google Scholar]
  25. Offord E. A., Beard P. A member of the activator protein 1 family found in keratinocytes but not in fibroblasts required for transcription from a human papillomavirus type 18 promoter. J Virol. 1990 Oct;64(10):4792–4798. doi: 10.1128/jvi.64.10.4792-4798.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Offord E. A., Chappuis P. O., Beard P. Different stability of AP1 proteins in human keratinocyte and fibroblast cells: possible role in the cell-type specific expression of human papillomavirus type 18 genes. Carcinogenesis. 1993 Dec;14(12):2447–2455. doi: 10.1093/carcin/14.12.2447. [DOI] [PubMed] [Google Scholar]
  27. Royer H. D., Freyaldenhoven M. P., Napierski I., Spitkovsky D. D., Bauknecht T., Dathan N. Delineation of human papillomavirus type 18 enhancer binding proteins: the intracellular distribution of a novel octamer binding protein p92 is cell cycle regulated. Nucleic Acids Res. 1991 May 11;19(9):2363–2371. doi: 10.1093/nar/19.9.2363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Sibbet G. J., Campo M. S. Multiple interactions between cellular factors and the non-coding region of human papillomavirus type 16. J Gen Virol. 1990 Nov;71(Pt 11):2699–2707. doi: 10.1099/0022-1317-71-11-2699. [DOI] [PubMed] [Google Scholar]
  29. Staedel C., Remy J. S., Hua Z., Broker T. R., Chow L. T., Behr J. P. High-efficiency transfection of primary human keratinocytes with positively charged lipopolyamine:DNA complexes. J Invest Dermatol. 1994 May;102(5):768–772. doi: 10.1111/1523-1747.ep12377673. [DOI] [PubMed] [Google Scholar]
  30. Tanaka M., Herr W. Differential transcriptional activation by Oct-1 and Oct-2: interdependent activation domains induce Oct-2 phosphorylation. Cell. 1990 Feb 9;60(3):375–386. doi: 10.1016/0092-8674(90)90589-7. [DOI] [PubMed] [Google Scholar]
  31. Thierry F., Spyrou G., Yaniv M., Howley P. Two AP1 sites binding JunB are essential for human papillomavirus type 18 transcription in keratinocytes. J Virol. 1992 Jun;66(6):3740–3748. doi: 10.1128/jvi.66.6.3740-3748.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Weitz J., Kopun M., Stoehr M., Napierski I., Royer H. D. A novel nuclear inhibitor I-92 regulates DNA binding activity of octamer binding protein p92 during the cell cycle. Nucleic Acids Res. 1991 Oct 25;19(20):5725–5730. doi: 10.1093/nar/19.20.5725. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Zeltner R., Borenstein L. A., Wettstein F. O., Iftner T. Changes in RNA expression pattern during the malignant progression of cottontail rabbit papillomavirus-induced tumors in rabbits. J Virol. 1994 Jun;68(6):3620–3630. doi: 10.1128/jvi.68.6.3620-3630.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. zur Hausen H. Human papillomaviruses in the pathogenesis of anogenital cancer. Virology. 1991 Sep;184(1):9–13. doi: 10.1016/0042-6822(91)90816-t. [DOI] [PubMed] [Google Scholar]
  35. zur Hausen H. Viruses in human cancers. Science. 1991 Nov 22;254(5035):1167–1173. doi: 10.1126/science.1659743. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES